Summary
Global Markets Direct’s, ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2016’, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
- The report reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics and enlists all their major and minor projects
- The report assesses Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG
AbbVie Inc.
Actinium Pharmaceuticals, Inc.
ADC Therapeutics Sarl
Affimed Therapeutics AG
Altor BioScience Corporation
Amgen Inc.
Ariad Pharmaceuticals, Inc.
Array BioPharma Inc.
AstraZeneca Plc
Atara Biotherapeutics, Inc.
Baxalta Incorporated
Bellicum Pharmaceuticals, Inc.
Bexion Pharmaceuticals, LLC.
Bio-Path Holdings, Inc.
BioSight Ltd.
Bristol-Myers Squibb Company
Calithera Biosciences, Inc.
Celator Pharmaceuticals, Inc.
Celgene Corporation
Cellectis S.A.
Cellular Biomedicine Group, Inc.
Ceronco Biosciences
Constellation Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
DiNonA Inc.
Effimune S.A.
Eli Lilly and Company
EpiZyme, Inc.
Erytech Pharma SA
Eureka Therapeutics, Inc.
Formula Pharmaceuticals, Inc.
Gamida Cell Ltd.
GlaxoSmithKline Plc
Hangzhou Minsheng Pharmaceutical Group Co.,Ltd
iDD biotech SAS
Immunomedics, Inc.
Incyte Corporation
Interprotein Corporation
Jasco Pharmaceuticals, LLC.
Johnson & Johnson
Juno Therapeutics Inc.
KaloBios Pharmaceuticals, Inc.
Karyopharm Therapeutics, Inc.
Kiadis Pharma B.V.
Kite Pharma, Inc.
medac GmbH
Merck & Co., Inc.
Mirna Therapeutics, Inc.
Nanovalent Pharmaceuticals Inc.
NantKwest, Inc.
Novartis AG
NovImmune SA
NuCana BioMed Limited
Omeros Corporation
Oncternal Therapeutics, Inc.
Oribase Pharma
Pfenex Inc.
Pfizer Inc.
Pharma Mar, S.A.
Polyphor Ltd.
Portola Pharmaceuticals, Inc.
Quimatryx, S.L.
Red5 Pharmaceuticals, LLC
Sanofi
Sareum Holdings Plc
Seattle Genetics, Inc.
Sellas Inc.
Sorrento Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Stemline Therapeutics, Inc.
Syros Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
TetraLogic Pharmaceuticals
Theravectys SA
Threshold Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc.
Tragara Pharmaceuticals, Inc.
Verastem, Inc.
Xbrane Biopharma AB
'
Table of Contents
Table of Contents 2
Introduction 7
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview 8
Therapeutics Development 9
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies 11
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes 18
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance 20
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies 23
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes 33
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development 35
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment 116
Drug Profiles 135
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Recent Pipeline Updates 456
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects 693
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products 699
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones 701
Appendix 710
List of Tables
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2016 28
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H1 2016 29
Number of Products under Development by Companies, H1 2016 30
Number of Products under Development by Companies, H1 2016 (Contd..1) 31
Number of Products under Development by Companies, H1 2016 (Contd..2) 32
Number of Products under Development by Companies, H1 2016 (Contd..3) 33
Number of Products under Development by Companies, H1 2016 (Contd..4) 34
Number of Products under Development by Companies, H1 2016 (Contd..5) 35
Number of Products under Development by Companies, H1 2016 (Contd..6) 36
Number of Products under Investigation by Universities/Institutes, H1 2016 38
Comparative Analysis by Late Stage Development, H1 2016 39
Comparative Analysis by Clinical Stage Development, H1 2016 40
Comparative Analysis by Early Stage Development, H1 2016 41
Products under Development by Companies, H1 2016 42
Products under Development by Companies, H1 2016 (Contd..1) 43
Products under Development by Companies, H1 2016 (Contd..2) 44
Products under Development by Companies, H1 2016 (Contd..3) 45
Products under Development by Companies, H1 2016 (Contd..4) 46
Products under Development by Companies, H1 2016 (Contd..5) 47
Products under Development by Companies, H1 2016 (Contd..6) 48
Products under Development by Companies, H1 2016 (Contd..7) 49
Products under Development by Companies, H1 2016 (Contd..8) 50
Products under Development by Companies, H1 2016 (Contd..9) 51
Products under Investigation by Universities/Institutes, H1 2016 52
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 53
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H1 2016 54
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc., H1 2016 55
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 56
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics Sarl, H1 2016 57
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Affimed Therapeutics AG, H1 2016 58
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Altor BioScience Corporation, H1 2016 59
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc., H1 2016 60
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 61
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Array BioPharma Inc., H1 2016 62
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AstraZeneca Plc, H1 2016 63
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Atara Biotherapeutics, Inc., H1 2016 64
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Baxalta Incorporated, H1 2016 65
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 66
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals, LLC., H1 2016 67
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings, Inc., H1 2016 68
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by BioSight Ltd., H1 2016 69
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2016 70
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Calithera Biosciences, Inc., H1 2016 71
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celator Pharmaceuticals, Inc., H1 2016 72
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celgene Corporation, H1 2016 73
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectis S.A., H1 2016 74
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 75
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ceronco Biosciences, H1 2016 76
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 77
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 78
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 79
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by DiNonA Inc., H1 2016 80
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Effimune S.A., H1 2016 81
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eli Lilly and Company, H1 2016 82
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by EpiZyme, Inc., H1 2016 83
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Erytech Pharma SA, H1 2016 84
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eureka Therapeutics, Inc., H1 2016 85
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Formula Pharmaceuticals, Inc., H1 2016 86
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd., H1 2016 87
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H1 2016 88
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Hangzhou Minsheng Pharmaceutical Group Co.,Ltd, H1 2016 89
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by iDD biotech SAS, H1 2016 90
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics, Inc., H1 2016 91
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Incyte Corporation, H1 2016 92
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Interprotein Corporation, H1 2016 93
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016 94
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Johnson & Johnson, H1 2016 95
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Juno Therapeutics Inc., H1 2016 96
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 97
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 98
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kiadis Pharma B.V., H1 2016 99
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kite Pharma, Inc., H1 2016 100
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by medac GmbH, H1 2016 101
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Merck & Co., Inc., H1 2016 102
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Mirna Therapeutics, Inc., H1 2016 103
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Nanovalent Pharmaceuticals Inc., H1 2016 104
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NantKwest, Inc., H1 2016 105
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Novartis AG, H1 2016 106
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NovImmune SA, H1 2016 107
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NuCana BioMed Limited, H1 2016 108
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Omeros Corporation, H1 2016 109
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oncternal Therapeutics, Inc., H1 2016 110
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oribase Pharma, H1 2016 111
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc., H1 2016 112
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc., H1 2016 113
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pharma Mar, S.A., H1 2016 114
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Polyphor Ltd., H1 2016 115
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 116
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Quimatryx, S.L., H1 2016 117
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Red5 Pharmaceuticals, LLC, H1 2016 118
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sanofi, H1 2016 119
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sareum Holdings Plc, H1 2016 120
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Seattle Genetics, Inc., H1 2016 121
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sellas Inc., H1 2016 122
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sorrento Therapeutics, Inc., H1 2016 123
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 124
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Stemline Therapeutics, Inc., H1 2016 125
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syros Pharmaceuticals, Inc., H1 2016 126
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 127
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by TetraLogic Pharmaceuticals, H1 2016 128
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Theravectys SA, H1 2016 129
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 130
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 131
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tragara Pharmaceuticals, Inc., H1 2016 132
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Verastem, Inc., H1 2016 133
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Xbrane Biopharma AB, H1 2016 134
Assessment by Monotherapy Products, H1 2016 135
Assessment by Combination Products, H1 2016 136
Number of Products by Stage and Target, H1 2016 138
Number of Products by Stage and Mechanism of Action, H1 2016 145
Number of Products by Stage and Route of Administration, H1 2016 151
Number of Products by Stage and Molecule Type, H1 2016 153
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics - Recent Pipeline Updates, H1 2016 475
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2016 712
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..1), H1 2016 713
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..2), H1 2016 714
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..3), H1 2016 715
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..4), H1 2016 716
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects (Contd..5), H1 2016 717
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H1 2016 718
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products (Contd..1), H1 2016 719
List of Figures
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2016 28
Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis, H1 2016 29
Number of Products under Development by Companies, H1 2016 30
Number of Products under Investigation by Universities/Institutes, H1 2016 37
Comparative Analysis by Late Stage Development, H1 2016 39
Comparative Analysis by Clinical Stage Development, H1 2016 40
Comparative Analysis by Early Stage Products, H1 2016 41
Assessment by Monotherapy Products, H1 2016 135
Assessment by Combination Products, H1 2016 136
Number of Products by Top 10 Targets, H1 2016 137
Number of Products by Stage and Top 10 Targets, H1 2016 137
Number of Products by Top 10 Mechanism of Actions, H1 2016 144
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 144
Number of Products by Routes of Administration, H1 2016 150
Number of Products by Stage and Routes of Administration, H1 2016 150
Number of Products by Top 10 Molecule Types, H1 2016 152
Number of Products by Stage and Top 10 Molecule Types, H1 2016 152
